CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 526 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
p38α inhibitor 9
CAS:p38α inhibitor9 (Compound 2015) is a p38α inhibitor that effectively blocks the enzyme activity of p38α, with an IC50 of less than 20 nM. It inhibits MK2T334 phosphorylation and activates Cdc25b and Cdc25c while inactivating Wee1, leading to mitotic catastrophe, aneuploidy or polyploidy, and DNA damage. Additionally, p38α inhibitor9 can suppress colorectal cancer (CRC) metastasis.Fórmula:C27H24FN3O3Forma y color:SolidPeso molecular:457.496CDK2 degrader 6
CAS:CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.Fórmula:C23H22F5N5O3Forma y color:SolidPeso molecular:511.44INX-315
CAS:INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.Fórmula:C19H21N7O3SPureza:99.88%Forma y color:SolidPeso molecular:427.48Haspin-IN-1
Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.Fórmula:C12H8N4O2SForma y color:SolidPeso molecular:272.28CDK5-IN-2
CAS:CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM).Fórmula:C29H28FN5OForma y color:SolidPeso molecular:481.56CDK1-IN-5
CDK1-IN-5 is a selective inhibitor for CDK1 (IC50: 42.19 nM), CDK2, CDK5, halting cancer cell growth.Fórmula:C27H26ClN5OSForma y color:SolidPeso molecular:504.05Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Fórmula:C19H20FN5OSForma y color:SolidPeso molecular:385.458CDK4/6-IN-3
CAS:CDK4/6-IN-3 is a brain-penetrant CDK4/CDK6 inhibitor (Kis: <0.3 nM and 2.2 nM) used for the treatment of glioblastoma. It inhibits CDK1 with a Ki of 110 nM.Fórmula:C25H31FN8Pureza:98%Forma y color:SolidPeso molecular:462.57CDK9/PARP-IN-1
CAS:CDK9/PARP-IN-1 (compound 37) is an inhibitor of CDK9 and PARP. It demonstrates IC50 values of 118 nM for CDK9 and 107 nM for PARP1. This compound exhibits a broad-spectrum anti-proliferative effect across various cancer cell lines.Fórmula:C38H34F2N8O3Forma y color:SolidPeso molecular:688.725YKL-1-116
CAS:YKL-1-116 is an effective, selective, and covalent CDK7 inhibitor.Fórmula:C34H38N8O3Pureza:98%Forma y color:SolidPeso molecular:606.72Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Fórmula:C14H14N4OSPureza:98.06%Forma y color:SolidPeso molecular:286.35Anticancer agent 30
<p>Anticancer agent 30 (6f-Z), a 3-arylidene-2-oxindole, selectively inhibits CDK2, showing potent anticancer potential.</p>Fórmula:C22H15ClFNOForma y color:SolidPeso molecular:363.81SGC-CLK-1
CAS:SGC-CLK-1 is a potent and selective inhibitor of Cdc2-like kinases CLK1, CLK2, and CLK4. It effectively inhibits the growth of melanoma and glioblastoma cells.Fórmula:C19H15F3N6O2Forma y color:SolidPeso molecular:416.36CDK2-IN-31
CAS:CDK2-IN-31 (compound I-125A) is an inhibitor of CDK2 and is utilized in cancer research.Fórmula:C37H52N6O5Forma y color:SolidPeso molecular:660.85CDK12/13 ligand 1
CAS:ALK-IN-29 (compound 4c) exhibits notable inhibitory activity against tyrosine kinases such as ALK, CDK2/CyclinE1, and FAK, with the strongest inhibition observed against ALK kinase, showing a 40.63% inhibition rate at a concentration of 10 μM. ALK-IN-29 is useful for cancer research.Fórmula:C26H26BrN5OForma y color:SolidPeso molecular:504.42Tizolemide
CAS:Tizolemide, a sulfonamide diuretic compound with alkaline properties, is cleared through the tubular transport system. It induces changes in the passive transport components across the basolateral membrane of isolated frog skin.Fórmula:C11H14ClN3O3S2Forma y color:SolidPeso molecular:335.83DDO-6079
CAS:DDO-6079 is an efficient CDC37 inhibitor. It suppresses the HSP90-CDC37 and CDC37-CDK4/6 chaperone complexes by binding to an allosteric site on CDC37. Additionally, DDO-6079 reduces the thermal stability of CDK6.Fórmula:C18H13ClN2O3Forma y color:SolidPeso molecular:340.76CDK7-IN-26
CAS:CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor with an IC50 of 7.4 nM. The compound effectively suppresses the growth of xenograft tumors derived from triple-negative breast cancer (TNBC) cell lines in vivo and has an IC50 of 0.15 μM for inhibiting MDA-MB-453 cells in vitro.Fórmula:C22H22FN6OPSPeso molecular:468.49CDK7-IN-18
CAS:CDK7-IN-18: potent, pyrimidine-based CDK7 inhibitor with cancer research potential.Fórmula:C22H24F3N7OSPureza:99.28%Forma y color:SolidPeso molecular:491.53CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Fórmula:C18H13N3O2Forma y color:SolidPeso molecular:303.31GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Fórmula:C22H23F4N5OPureza:98.88%Forma y color:SolidPeso molecular:449.44LY3143921 hydrate
CAS:LY3143921 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor with broad in vitro anticancer activity [1].Fórmula:C16H14FN5O2Pureza:98.43%Forma y color:SolidPeso molecular:327.31Tanuxiciclib
CAS:Tanuxiciclib is a cyclin dependent kinase (CDK) inhibitor, specifically designed to interfere with cell cycle progression by inhibiting the activity of CDKs, which are crucial regulators of cell division.Fórmula:C15H13FN6OForma y color:SolidPeso molecular:312.308GSK-3/CDK5/CDK2-IN-1
CAS:GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1].Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.433Tibremciclib
CAS:<p>Tibremciclib is a cyclin-dependent kinase 4 (CDK4) inhibitor that exhibits antineoplastic properties [1].</p>Fórmula:C28H32F2N8Pureza:98%Forma y color:SolidPeso molecular:518.6YK-2168
CAS:<p>YK-2168 is a differentiated selective inhibitor of CDK9.</p>Fórmula:C16H18ClN5Forma y color:SolidPeso molecular:315.80Ref: TM-T200769
Producto descatalogado
